USRE34756E - Excretion of potassium ion by prostanoic acid derivatives - Google Patents
Excretion of potassium ion by prostanoic acid derivatives Download PDFInfo
- Publication number
- USRE34756E USRE34756E US07/953,786 US95378692A USRE34756E US RE34756 E USRE34756 E US RE34756E US 95378692 A US95378692 A US 95378692A US RE34756 E USRE34756 E US RE34756E
- Authority
- US
- United States
- Prior art keywords
- prostanoic acid
- derivative
- potassium ion
- oxo
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229910001414 potassium ion Inorganic materials 0.000 title claims abstract description 40
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 title claims abstract description 36
- 230000029142 excretion Effects 0.000 title claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 37
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 230000001939 inductive effect Effects 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 210000000936 intestine Anatomy 0.000 claims description 6
- 201000006370 kidney failure Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 230000003907 kidney function Effects 0.000 claims description 4
- 150000003180 prostaglandins Chemical class 0.000 claims description 4
- 208000002682 Hyperkalemia Diseases 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 150000001721 carbon Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 101150108015 STR6 gene Proteins 0.000 claims 1
- -1 for example Chemical group 0.000 description 35
- 239000000203 mixture Substances 0.000 description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 22
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 150000002576 ketones Chemical group 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000003608 fece Anatomy 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229940097362 cyclodextrins Drugs 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CZEBTZMIQZVUSE-UHFFFAOYSA-N [6-cyano-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid Chemical compound C1=C(C#N)C=C2N(C(=O)OC(C)(C)C)C(B(O)O)=CC2=C1 CZEBTZMIQZVUSE-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 238000006809 Jones oxidation reaction Methods 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KZGNJLHBTZMSMD-UHFFFAOYSA-N C[Cu]C Chemical compound C[Cu]C KZGNJLHBTZMSMD-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101150020741 Hpgds gene Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical class CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 1
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- ROUDCKODIMKLNO-CTBSXBMHSA-N 6-oxoprostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC(=O)CCCCC(O)=O ROUDCKODIMKLNO-CTBSXBMHSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- BXLYSRPHVMCOPS-ACZMJKKPSA-N Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO BXLYSRPHVMCOPS-ACZMJKKPSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- CDZHZLQKNAKKEC-UHFFFAOYSA-N [bis(hydroxymethylamino)methylamino]methanol Chemical class OCNC(NCO)NCO CDZHZLQKNAKKEC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 238000006704 dehydrohalogenation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- OFGLXRANLNLCHY-HBMCJLEFSA-N ethyl 7-[(1r,2s,3s)-3-hydroxy-2-(7-methyl-3-oxooctyl)-5-oxocyclopentyl]-6-oxoheptanoate Chemical group CCOC(=O)CCCCC(=O)C[C@@H]1[C@H](CCC(=O)CCCC(C)C)[C@@H](O)CC1=O OFGLXRANLNLCHY-HBMCJLEFSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical group CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- DUBAHWYGBSQRDZ-ILWGZMRPSA-N methyl 7-[(1r,2s,3s)-3-methyl-5-oxo-2-(3-oxodecyl)cyclopentyl]hept-5-enoate Chemical group CCCCCCCC(=O)CC[C@H]1[C@@H](C)CC(=O)[C@@H]1CC=CCCCC(=O)OC DUBAHWYGBSQRDZ-ILWGZMRPSA-N 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Definitions
- the present invention relates to a method for improvement of extracorporeal excretion of potassium ion and inducing decrease in potassium ion concentration in the blood which comprises administering a prostanoic acid derivative to a subject.
- the object of the present invention is to reduce potassium ion concentration in the blood or improve extracorporeal excretion of potassium ion in the treatment of conditions wherein potassium ion concentration in the blood is increased, e.g. hyperkalemia or renal insufficiency.
- potassium ion in the blood is excreted into the urine through the kidneys.
- potassium ion is excreted through the intestinal wall as an alternative main route, and this route is effective for a patient whose renal function is reduced or injured. This method of excretion may be called "intracorporeal dialysis".
- Renal insufficiency refers to a condition in which renal function is injured by renal diseases such as glamerulonephritis, nephrotic syndrome, nephrosclerosis, renal carcinoma, lupus nephritis etc.
- renal diseases such as glamerulonephritis, nephrotic syndrome, nephrosclerosis, renal carcinoma, lupus nephritis etc.
- One important parameter for renal insufficiency is the excreting function of kidney and especially the concentration of potassium ion in the blood which are pooled in the body by injured excretion. Symptom of hyperkalemia appears as the pooling progresses.
- dialysis Traditional means effective in the treatment of renal insufficiency is the so-called dialysis in which the blood is contacted with a dialysate with a semipermeable membrane between them whereby substances in the blood may be removed through diffusion by osmotic gradient.
- the dialysis include hemokialysis in which the arterial blood is introduced into an artificial kidney and returned to a vein and peritoneal dialysis in which blood substances are dispersed into a dialysate, which is introduced into the peritoneal cavity and discharged periodically, through capillary vessels serving as a semipermeable membrane.
- the former has disadvantage that it requires a sergical operation such as shunt operation while the latter has disadvantages that it has inferior dialysis efficacy and requires infection-preventing measures.
- prostaglandin is referred to as PG
- enteropooling activity activity of pooling water in intestines
- Enteropooling activity of 16,16-dimethyl-PGE 2 has also been described in Prostaglandins, 11, 809-828(1976).
- prostanoic acid derivatives have activity of excreting potassium ion.
- the present invention provides a method for inducing decrease in potassium ion concentration in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, a prostanoic acid derivative in an amount effective in inducing decrease in potassium ion concentration in the blood wherein said concentration is increased.
- the present invention provides a method for improving extracorporeal excretion of potassium ion in the blood which comprises administering, to a subject in need of such treatment, an amount, effective in improving extracorporeal excretion of potassium ion in the blood, of a prostanoic acid derivataive.
- the present invention provides a use of a prostanoic acid derivative for the manufacture of a medicament for inducing decrease in potassium ion concentration in the blood.
- the present invention provides a use of a prostanoic acid derivative for the manufacture of a medicament for improving extracorporeal excretion of potassium in the blood of a patient having an increased potassium ion concentration in the blood.
- the present invention provides a pharmaceutical composition for inducing decrease in potassium ion concentration in the blood comprising a prostanoic acid derivative in association with a pharmaceutically acceptable carrier, diluent or excipient.
- the present invention provides a pharmaceutical composition for improving extracorporeal excretion of potassium ion in the blood of a patient having an increased potassium ion concentration in the blood comprising a prostanoic acid derivative in association with a pharmaceutically acceptable carrier, diluent or excipient.
- extracorporeal excretion means active or passive transport of substances in the body fluid, principally in the blood, into the urine or feces through the intestine ranging from duodenum to large intestine, principally through small intestine.
- PG peptide-like compound
- the primary PGs are classified based on the structural feature of the five-membered cycle moiety into PGAs, PGBs, PGCs, PGDs, PGEs, PGFs, PGGs, PGHs, PGIs and PGJs, and also on the presence or absence of unsaturation and oxidation in the chain moiety as:
- PGFs are sub-classified according to the configration of hydroxy group at 9 into ⁇ (hydroxy group being in the alpha configration) and ⁇ (hydroxy group being in the beta configration).
- Some synthetic analogues have somewhat modified skeletons.
- derivative refers to a compound in which one or more atom or group in the prostanoic acid shown by the formula (A) is replaced by other atom or group or eliminated.
- derivatization includes the modifications known in the synthetic PG analogues and other modifications.
- Nomenclature of prostanoic acid derivatives herein uses the numbering system of prostanoic acid represented in formula (A) shown above.
- formula (A) shows a basic skeleton having a twenty carbon atoms
- the 15-keto-PG compounds used in the present invention are not limited to those having the same number of carbon atoms.
- the carbon atoms in Formula (A) are numbered 2 to 7 on the ⁇ -chain starting from the ⁇ -carbon atom adjacent to the carboxylic carbon atom which is numbered 1 and towards the five-membered ring, 8 to 12 on the said ring starting from the carbon atom on which the ⁇ -chain is attached, and 13 to 20 on the ⁇ -chain starting from the carbon atom adjacent to the ring.
- PGDs, PGEs and PGFs have (a) hydroxy group(s) on the carbon atom(s) at position 9 and/or 11 but in the present specification PGs include those having a group other than a hydroxyl group at position 9 and/or 11. Such PGs are referred to as 9-dehydroxy-9-substituted-PG compounds or 11-dehydroxy-11-substituted-PG compounds.
- prostanoic acid derivative is based upon the prostanoic acid and sometimes utilizes abbreviation "PG" for convenience, when the derivative in question has a partial structural common with PGs.
- PG abbreviation
- these compounds can also be named according to the IUPAC naming system.
- 13,14-dihydro-15-keto-16R,S-fluoro-PGE 2 is (Z)-7- ⁇ (1R,2R,3R)-3-hydroxy-2[(4R,S)-4-fluoro-3-oxo-1-octyl]-5-oxocyclopentyl ⁇ -hept-5-enic acid.
- 13,14-dihydro-15-keto-20-ethyl-11-dehydroxy-11R-methyl-PGE 2 methyl ester is methyl 7- ⁇ (1R,2S,3S)-3-methyl-2-[3-oxo-1-decyl]-5-oxo-cyclopentyl ⁇ -hept-5-enoate.
- 13,14-dihydro-6,15-diketo-19-methyl-PGE 2 ethyl ester is ethyl 7- ⁇ (1R,2S,3S)-3-hydroxy-2-(7-methyl-3-oxo-1-octyl)-5-oxo-cyclopentyl ⁇ -6-oxo-heptanoate.
- 13,14-dihydro-15-keto-20-ethyl-PGF 2 ⁇ isopropyl ester is isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy- 2- ⁇ 3-oxo-1-decyl)-cyclopentyl]hept-5-enoate.
- 13,14-dihydro-15-keto-20-methyl-PGF 2 ⁇ methyl ester is methyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2- ⁇ 3-oxo-1-nonyl ⁇ -cyclopentyl]-hept-5-enonate.
- Preferred prostanoic acid derivatives used in the present are those having an oxo group at position 15 of the prostanoic acid in place of the hydroxy group, or having at least one halogen atom on the prostanoic acid skeleton, or having both of these features. These derivatives may have a single bond (15-keto-PG 1 compounds), a double bond (15-keto-PG 2 compounds) between positions 5 and 6, or two double bonds (15-keto-PG 3 compounds) between positions 5 and 6 as well as positions 17 and 18.
- halogen refers to fluorine, chlorine, bromine and iodine with fluorine being preferred.
- substitution products or derivatives include esters at the carboxy group at the alpha chain, pharmaceutically or physiologically acceptable salts, unsaturated derivatives having a double bond or a triple bond between positions 2 and 3 or positions 5 and 6, respectively, substituted derivatives having substituent(s) on carbon atom(s) at position 3, 6, 16, 17, 19 and/or 20 and compounds having lower alkyl or a hydroxy (lower) alkyl group at position 9 and/or 11 in place of the hydroxy group, of the above PGs.
- Substituents on the carbon atom at position 3, 17 and/or 19 include lower alkyl, for example, C 1-4 alkyl, especially methyl and ethyl.
- Substituents on the carbon atom at position 16 include lower alkyl e.g. methyl, ethyl etc., hydroxy and halogen atom e.g. chlorine, fluorine, phenyl and phenoxy, the last two being unsubstituted or substituted.
- Substituents on the carbon atom at position 20 include saturated and unsaturated lower alkyl e.g. C 1-4 alkyl, lower alkoxy e.g.
- C 1-4 alkoxy and lower alkoxy (lower)alkyl e.g C 1-4 alkoxy-C 1-4 alkyl
- Substituents on the carbon atom at position 6 include oxo group forming carboxyl.
- Stereochemistry of PGs having hydroxy, lower alkyl or lower (hydroxy)alkyl substituent on the carbon atom at position 9 and/or 11 may be alpha, beta or mixtures thereof.
- Said derivatives may have an alkoxy, phenoxy or phenyl group at the end of the omega chain where the chain is shorter than the primary PGs.
- preferred compounds are those having at least one halogen atom on the prostanoic acid derivative, and the position of halogen atom is not limited but preferredly on the omega chain and more preferredly one or two halogen atoms are present at position 16.
- a group of preferred compounds used in the present invention has the formula (I) ##STR2## wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-members ring may have at least one double bond, Z is hydrogen or halogen, A is --CH 2 OH, --COCH 2 OH, --COOH or is functional derivative, R 1 is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl, R 2 is saturated or unsaturated, lower or mediumaliphatic hydrocarbon residue which is unsubstituted or substituted with oxo, hydroxy, halo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy, with the proviso the
- the term "unsaturated" in the definitions for R 1 and R 2 is intended to include at least one and optionally more then one double bond and/or triple bond isolatedly, separately or serially present between carbon atoms of the main and/or side chains. According to usual nomenclature, an unsaturation between two serial positions is represented by denoting the lower number of said two positions, and an unsaturation between two distal positions is represented by denoting both of the positions. Preferred unsaturation is a double bond at position 2 and a double or triple bond at position 5.
- lower or medium aliphatic hydrocarbon residue refers to a straight or branched chain hydrocarbyl group having 1 to 14 carbon atoms (for a side chain, 1 to 3 carbon atoms being preferred) and preferably 2 to 8 carbon atoms for R 1 and 6 to 12 carbon atoms for R 2 .
- halo denotes fluoro, chloro, bromo and iodo.
- lower is intended to include a group having 1 to 6 carbon atoms unless otherwise specified.
- lower alkyl as a group or a moiety in hydroxy(lower)alkyl includes saturated and straight or branched chain hydrocarbon radicals containing 1 to 6, carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.
- lower alkoxy refers to the group lower-alkyl-O- wherein lower alkyl is as defined above.
- hydroxy(lower)alkyl refers to alkyl as defined above and substituted with at least one hydroxy group, e.g. hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 1-methyl-1-hydroxyethyl.
- lower alkanoyloxy refers to a group of the formula: RCO--O-- wherein RCO-- is an acyl group formed by oxidation of a lower alkyl group as defined above, e.g. acetyl.
- cyclo(lower)alkyl refers to a cyclic group formed by cyclization of a lower alkyl group as defined above.
- aryl includes unsubstituted or substituted aromatic carbocyclic or heterocyclic (preferably monocyclic) groups, e.g. phenyl, tolyl, xylyl and thienyl.
- substituents are halo and halo(lower)alkyl wherein halo and lower alkyl being as defined above.
- aryloxy refers to a group of the formula: ArO-- wherein Ar is aryl as defined above.
- the term "functional derivative" of carboxy as A includes salts (preferably pharmaceutically acceptable salts), esters and amides.
- Suitable “pharmaceutically acceptable salts” includes conventional non-toxic salt, and may be a salt with an inorganic base, for example a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), ammonium salt, a salt with an organic base, for example, an amine salt (e.g.
- methylamine salt dimethylamine salt, cyclohexylamine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris(hydroxymethylamino)methane salt, monomethyl-monoethanolamine salt, procaine salt, caffeine salt, etc.), basic amino acid salt (e.g. arginine salt, lysine salt, etc.), tetraalkylammonium salt and the like.
- These salts can be prepared by the conventional process, for example from the corresponding acid and base or by salt interchange.
- esters are aliphatic esters, for example, lower alkyl ester e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, 1-cyclopropylethyl ester, etc., lower alkenyl ester e.g. vinyl ester, allyl ester, etc., lower alkynyl ester e.g. ethynyl ester, propynyl ester, etc., hydroxy(lower)alkyl ester e.g.
- lower alkyl ester e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, 1-cyclopropylethyl ester, etc
- hydroxyethyl ester lower alkoxy(lower)-alkyl ester e.g. methoxymethyl ester, 1-methoxyetyl ester, etc.
- aromatic esters for example, optionally substituted aryl ester e.g. phenyl ester, tosyl ester, t-butylphenyl ester, salicyl ester, 3,4-di-methoxy-phenyl ester, benzamidophenyl ester etc., aryl(lower)alkyl ester e.g. benzyl ester, trityl ester, benzhydryl ester, etc.
- aryl ester e.g. benzyl ester, trityl ester, benzhydryl ester, etc.
- amides are mono- or di- lower alkyl amides e.g. methylamide, ethylamide, dimethylamide, etc., arylamide e.g. anilide, toluidide, and lower alkyl- or aryl-sulfonylamide e.g. methylsulfonylamide, ethylsulfonylamide, tolylsulfonylamide etc.
- Preferred examples of A include --COOH, --COOCH 3 , --COOCH 2 CH 3 , --COOCH(CH 3 ) 2 ) and --CONHSO 2 CH 3 .
- the configuration of the ring and the ⁇ - and/or omega chain in the above formula (I) may be the same as or different from that in the primary PGs.
- the present invention also includes a mixture of a compound having a primary configuration and that of an unprimary configuration.
- Examples of the typical compounds of the present invention are 15-keto-PGs, 13,14-dihydro-15-keto-PGs and their e.g. 6-keto-derivatives, ⁇ 2 -derivatives, 3R,S-methyl-derivatives, 16R,S-methylderivatives, 16,16-dimethyl-derivatives, 16R,S-fluoroderivatives, 16,16-difluoro-derivatives, 17S-methylderivatives, 19-methylderivatives, 20-methyl-derivatives and 16-desbutyl-16-phenoxy derivatives.
- 15-keto-PG compounds of the present invention When 15-keto-PG compounds of the present invention have a saturated bond between positions 13 and 14, these compounds may be in the keto-hermiacetal equilibrium by forming a hemiacetal between hydroxy group at position 11 and ketone at position 15.
- the proportion of both tautomeric isomers, when presnt, varies depending on the structure of the rest of the molecule or kind of any substituent present and, sometimes, one isomer may predominantly be present in comparison with the other.
- the compounds used in the invention include both isomers.
- the compounds used in the invention may be represented by a structure or name based on keto-form regardless of the presence or absence of the isomers, it is to be noted that such structure or name does not intend elimination of the hemiacetal type of compounds.
- any of the individual tautomeric isomers, a mixture thereof, or optical isomers, a mixture thereof, a racemic mixture, and other isomers such as steric isomers can be used in the same purpose.
- Some of the compounds used in the present invention may be prepared by the method disclosed in Japanese Patent Publication (unexamined) No. A-52753/1989.
- these compounds may be prepared by a process analogous to that described herein or to known processes.
- a practical preparation of the prostanoic acid derivative involves the following steps; referring to the synthetic charts(I) to (III), reaction of the aldehyde (2) prepared by the Collins oxidation of commercially available (-)-Corey lactone (1) with dimethyl (2-oxoheptyl)phosphate anion to give ⁇ , ⁇ -unsaturated ketone (3), reduction of the ⁇ , ⁇ -unsaturated ketone (3) to the corresponding saturated ketone (4), protection of the carbonyl group of the ketone (4) with a diol to the corresponding ketal (5), and deprotection of the p-phenylbenzoyl group to give the corresponding alcohol (6) followed by protection of the newly derived hydroxy group with dihydropyrane to give the corresponding tetrahydropyranyl ether (7).
- a precursor of PGEs wherein the ⁇ -chain is a 13,14-
- 6-keto-PGE 1 s (15) of which a group constituted with carbon atoms of position 5, 6 or 7 is --C 5 H 2 --C 6 (O)--C 7 H 2 --, may be prepared in the following steps; reduction of the tetrahydropyranyl ether (7) with, for example, diisobutyl aluminum hydride to give the corresponding lactol (8), reaction of the lactol (8), with the ylide generated from (4-carboxybutyl)triphenyl phosphonium bromide followed by esterification (10), cyclization between the 5,6-double bond and the hydroxyl group at position 9 with NBS or iodine to give the halogenated compound (11), dehydrohalogenation of the compound (11) with, for example, DBU to give the 6-keto compound (13) followed by Jones oxidation and removal of the protecting groups.
- PGE 2 s (19) of which a group constituted with carbon atoms of position 5, 6 and 7 is --C 7 H 2 --C 6 H ⁇ C 5 H-- may be prepared in the following steps; as shown in the synthetic chart II, reduction of the above tetrahydropyranyl ether (7) to give the lactol (8), reaction of the resultant lactol (8) with the ylide derived from (4--carboxybutyl-)triphenyl phosphonium bromide to give the carboxylic acid (16) followed by esterification to give ester (17), Jones oxidation of the esters (17) to give the compound (18), and removal of the protecting groups.
- the compound having --C 7 H 2 --C 6 H 2 --C 5 H 2 -- may be prepared by using the same process as that for preparing PGE 2 having --CH 2 CH ⁇ CH-- and subjecting the resultant compound (18) to catalytic reduction to reduce the double bond between the position 5 and 6 followed by removal of the protective groups.
- Synthesis of 5,6-dehydro-PGE 2 s having --C 7 H 2 --C 6 .tbd.C 5 -- may be carried out by capturing a copper enolate formed by 1,4-addition of a monoalkylcopper complex or a dialkylcopper complex of the following formulae: ##STR3## to 4R-t-butyldimethylsilyloxy-2-cyclopenten-1-one with 6-alkoxycarbonyl-1-iodo-2-hexyne or the derivatives.
- the 11- ⁇ type PGEs can be prepared according to the synthetic chart III.
- PGE derivatives having a methyl group at position 11 in place of hydroxy can be prepared by reacting a dimethyl copper complex with PGA-type compound obtained by subjecting 9-hydroxy-11-tosylate to the Jones oxidation.
- they can be prepared by protecting the carbonyl of saturated ketone (4) produced by reducing unsaturated ketone (3), eliminating p-phenylbenzoyl and tosylating the produced alcohol, treating with DBU to form a lactol, introducing the alpha-chain by Wittig reaction, oxidizing the alcohol at position 9 to give PGA-type compound, and reacting the product with dimethyl copper complex in order to introduce a methyl group into position 11 to give an 11-methyl-PGE-type compound, which on reduction with e.g.
- an 11-methyl-PGF-type compound is obtained by a benzophenone-sensitized photoaddition of methanol of PGA-type compound, which is reduced with, e.g. sodium borohydride, to give an 11-hydroxymethyl-PGF-type compound.
- the synthetic route for the compounds used in the present invention is not limited to the that described above one and may vary using different protecting, reducing and/or oxidizating methods.
- the compounds used in the present invention may be used as a medicine for animals and human beings and usually applied systemically or locally by such methods as oral administration, intravenous injection (including instillation), subcutaneous injection, suppository and the like. While the dosage will vary depending on the particular animal or human patient, age, body weight, symptom to be treated, desired therapeutic effect, administration route, term of treatment and the like, satisfactory effects will be obtained with the dosage of 0.001-500 mg/kg administered in 2 to 4 divided doses a day or as a sustained form.
- solid composition of this invention for oral administration, tablets, troches, buccals, capsules, pills, powders, granules and the like are included.
- the solid composition containing one or more active substances is mixed with at least an inactive diluent, e.g. lactose, mannitol, glucose, hydrocypropyl cellulose, fine crystalline cellulose, starch, polyvinyl pyrolidone, magnesium aluminate metasilcate.
- the composition may contain additives other than the inactive diluent, for example, lubricants e.g., magnesium stearae, a disintegrator e.g. cellulose calcium gluconates, stabilizers e.g.
- cyclodextrins may increase the stability of the compounds by forming an inclusion compounds. The stability may be often increased by forming lyposome with phospholipids.
- Tablets and pills may be coated with an enteric or gastroenteric film e.g. white sugar, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalates and the like, if necessary, and furthermore they may be covered with two or more layers.
- the composition may be in the form of capsules made of substance easily absorbed e.g. gelatin.
- the composition may be in the form of buccals, when an immediated effect is desired.
- base e.g. glycerine, lactose may be used.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like and contain a generally used inactive diluent e.g. purified water or ethyl alcohol.
- the composition may contain additives e.g. wetting agents, suspending agents, sweeteners, flavors, perfumes and preservatives.
- composition of the present invention may be sprays which may contain one or more active ingredients and which can be prepared according to a well known methods.
- An injection of this invention for non-oral administration includes serile aqueous or nonaqueous solutions, suspensions, and emulsions.
- Diluents for the aqueous solution or suspension include, for example, distilled water for injection, physiological saline and Ringer's solution.
- Diluents for the nonaqueous solution and suspension include, for example, propylene glycol, polyethylene glycol, vegetable oils e.g. olive oil, alcohols, e.g. ethanol and polysorbates.
- the composition may contain other additives, e.g. preservatives, wetting agents, emulsifying agents, dispersing agents and the like. These are sterilized by filtration through, e.g. a bacteria-retaining filter, compounding with a sterilizer, gas sterilization or radiation sterilization. These can be prepared by producing a sterilized water or a sterilized solvent for injection before use.
- Another formulation according to the present invention is a rectal or vaginal suppository.
- This can be prepared by mixing at least one active compound according to the invention with a suppository base e.g. cacao butter and optionally containing nonionic surfactant for improving absorption.
- a suppository base e.g. cacao butter and optionally containing nonionic surfactant for improving absorption.
- the compounds used in the medicament according to the present invention have an effect of inducing decrease in potassium ion concentration or of improving excretion of potassium ion concentration in the blood into the intestines or as feces.
- the compounds used in the present invention are useful for treatment (e.g. prevention, cure, relief and arrest or relief of development) of conditions wherein potassium ion level in the blood is elevated and of disorder in the balance of electrolytes such as uremia irrespective of cause, e.g. disease, drug or food.
- the powders thus obtained were mixed with fine-grain silica gel (Aerosil*, 200 g) and filled in No.3 hard gelatin capsules (100) to give enteric capsules which contain 0.5 mg of 13,14-dihydro-15-keto-16-desbutyl-16-m-trifluoromethylphenoxy-PGF 2 .alpha. methyl ester per capsule.
- the active ingredient can be replaced by any other compound within the compounds used in the invention.
- Wistar rats (5 weeks old, obtained from Charles River) were quarantined and acclimatized for about 1 weeks. Then the animals were divided into groups with even mean weight and standard deviation.
- All the animals were bred in individual stainless steel cages (190 ⁇ 380 ⁇ 180 mm) at a temperature of 24° ⁇ 1° C. and with a humidity of 55 ⁇ 5% with 12 hour light and dark cycle (illumination 8:00-20:00) supplying with fresh aseptic air. They were bred (with NMF, Oriental Yeast Industries, Ltd) and waterad ad libitum exept the last day of medication, on which day they were fasted.
- Test compound 13,14-dihydro-15-keto-16-R,S-fluoroprostaglandin E 2 was dissolved in an aliquot of ethanol and the solution was evaporated in a test tube under nitrogen. The residue was combined with a predetermined amount of distilled water and sonicated to form a homogeneous test suspension.
- rats received (between 9:00 and 12:00) a daily dosage of 1 ml/1 kg of the test suspension through a disposable plastic sylinge (1 ml) equipped with an P.O. administration needle for rat based on the body weight measured just before the administration.
- rats were sacrificed by cervical dislocation and subjected to celiotomy. Intestine was ligated at pyloric part of stomach and upper cecal part. The whole small intestine was removed and intraintestinal content was collected, measured a volume and centrifuged for 5 minutes at 1000 rpm and suppernatant was separated.
- the urine, serum and supernatant were assayed for electoylte concentrations.
- Test Example 2 The procedure of Test Example 2 was repeated except that 13,14-dihydro-15-keto-16,16-difluoro-PGE 2 (1.0 mg/kg) was used as the test compound. Contents of electorlyte in feces (after 5 days of medication) and in the serum (after 7 days of medication) are shown in the following Tables.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Amethod for inducing decrease in potassium ion concentration in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, a prostanoic acid derivative in an amount effective in inducing decrease in potassium ion concentration in the blood wherein said concentration is increased or for improving extracorporeal excretion of potassium ion in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, a prostanoic acid derivative in an amount effective in improving extracorporeal excretion of potassium ion concentration is increased.
Description
1. Field of the Invention
The present invention relates to a method for improvement of extracorporeal excretion of potassium ion and inducing decrease in potassium ion concentration in the blood which comprises administering a prostanoic acid derivative to a subject.
The object of the present invention is to reduce potassium ion concentration in the blood or improve extracorporeal excretion of potassium ion in the treatment of conditions wherein potassium ion concentration in the blood is increased, e.g. hyperkalemia or renal insufficiency. Generally, potassium ion in the blood is excreted into the urine through the kidneys. According to the present invention, however, potassium ion is excreted through the intestinal wall as an alternative main route, and this route is effective for a patient whose renal function is reduced or injured. This method of excretion may be called "intracorporeal dialysis".
Renal insufficiency refers to a condition in which renal function is injured by renal diseases such as glamerulonephritis, nephrotic syndrome, nephrosclerosis, renal carcinoma, lupus nephritis etc. One important parameter for renal insufficiency is the excreting function of kidney and especially the concentration of potassium ion in the blood which are pooled in the body by injured excretion. Symptom of hyperkalemia appears as the pooling progresses.
Traditional means effective in the treatment of renal insufficiency is the so-called dialysis in which the blood is contacted with a dialysate with a semipermeable membrane between them whereby substances in the blood may be removed through diffusion by osmotic gradient. The dialysis include hemokialysis in which the arterial blood is introduced into an artificial kidney and returned to a vein and peritoneal dialysis in which blood substances are dispersed into a dialysate, which is introduced into the peritoneal cavity and discharged periodically, through capillary vessels serving as a semipermeable membrane. However, the former has disadvantage that it requires a sergical operation such as shunt operation while the latter has disadvantages that it has inferior dialysis efficacy and requires infection-preventing measures.
2. Background Information
The present invention and co-workers formerly discovered that 15-keto-16-halo-prostaglandins (hereinafter, prostaglandin is referred to as PG) have an enteropooling activity (activity of pooling water in intestines) (EP-A-310305). Enteropooling activity of 16,16-dimethyl-PGE2 has also been described in Prostaglandins, 11, 809-828(1976). However, nothing has been reported about the fact that prostanoic acid derivatives have activity of excreting potassium ion.
As a result of extensive studies about the properties of PG compounds, the present inventors unexpectedly discovered that these compounds have an activity of decreasing potassium ion concentration in the blood and excreting potassium ion.
In a first aspect, the present invention provides a method for inducing decrease in potassium ion concentration in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, a prostanoic acid derivative in an amount effective in inducing decrease in potassium ion concentration in the blood wherein said concentration is increased.
In a second aspect, the present invention provides a method for improving extracorporeal excretion of potassium ion in the blood which comprises administering, to a subject in need of such treatment, an amount, effective in improving extracorporeal excretion of potassium ion in the blood, of a prostanoic acid derivataive.
In a third aspect, the present invention provides a use of a prostanoic acid derivative for the manufacture of a medicament for inducing decrease in potassium ion concentration in the blood.
In a fourth aspect, the present invention provides a use of a prostanoic acid derivative for the manufacture of a medicament for improving extracorporeal excretion of potassium in the blood of a patient having an increased potassium ion concentration in the blood.
In a fifth aspect, the present invention provides a pharmaceutical composition for inducing decrease in potassium ion concentration in the blood comprising a prostanoic acid derivative in association with a pharmaceutically acceptable carrier, diluent or excipient.
In a sixth aspect, the present invention provides a pharmaceutical composition for improving extracorporeal excretion of potassium ion in the blood of a patient having an increased potassium ion concentration in the blood comprising a prostanoic acid derivative in association with a pharmaceutically acceptable carrier, diluent or excipient.
The expression "extracorporeal excretion" means active or passive transport of substances in the body fluid, principally in the blood, into the urine or feces through the intestine ranging from duodenum to large intestine, principally through small intestine.
The term "prostanoic acid" refers to the basic skeleton, show by the formula below, as the common structural feature of the naturally occurring PGs. ##STR1## The primary PGs are classified based on the structural feature of the five-membered cycle moiety into PGAs, PGBs, PGCs, PGDs, PGEs, PGFs, PGGs, PGHs, PGIs and PGJs, and also on the presence or absence of unsaturation and oxidation in the chain moiety as:
Subscript 1 - - - 15-OH
Subscript 2 - - - 5,6-unsaturated-15-OH
Subscript 3 - - - 5,6- and 17, 18-diunsaturated-15-OH
Further, PGFs are sub-classified according to the configration of hydroxy group at 9 into α(hydroxy group being in the alpha configration) and β(hydroxy group being in the beta configration). Some synthetic analogues have somewhat modified skeletons.
The term "derivative" refers to a compound in which one or more atom or group in the prostanoic acid shown by the formula (A) is replaced by other atom or group or eliminated. Such derivatization includes the modifications known in the synthetic PG analogues and other modifications.
Nomenclature of prostanoic acid derivatives herein uses the numbering system of prostanoic acid represented in formula (A) shown above.
While formula (A) shows a basic skeleton having a twenty carbon atoms, the 15-keto-PG compounds used in the present invention are not limited to those having the same number of carbon atoms. The carbon atoms in Formula (A) are numbered 2 to 7 on the α-chain starting from the α-carbon atom adjacent to the carboxylic carbon atom which is numbered 1 and towards the five-membered ring, 8 to 12 on the said ring starting from the carbon atom on which the α-chain is attached, and 13 to 20 on the ω-chain starting from the carbon atom adjacent to the ring. When the number of carbon atoms is decreased in the α-chain, the number is deleted in order starting from position 2 and when the number of carbon atoms is increased in the α-chain, compounds are named as substituted derivatives having respective substituents at position 1 in place of carboxy group (C-1). Similarly, when the number of carbon atoms is decreased in the ω-chain, the number is deleted in order starting from position 20 and when the number of carbon atoms is increased in the ω-chain, compounds are named as substituted derivatives having respective substituents at position 20. Stereochemistry of the compounds is the same as that of above formula (A) unless otherwise specified.
In general, PGDs, PGEs and PGFs have (a) hydroxy group(s) on the carbon atom(s) at position 9 and/or 11 but in the present specification PGs include those having a group other than a hydroxyl group at position 9 and/or 11. Such PGs are referred to as 9-dehydroxy-9-substituted-PG compounds or 11-dehydroxy-11-substituted-PG compounds.
As stated above, nomenclature of the prostanoic acid derivative is based upon the prostanoic acid and sometimes utilizes abbreviation "PG" for convenience, when the derivative in question has a partial structural common with PGs. These compounds, however, can also be named according to the IUPAC naming system. For example, 13,14-dihydro-15-keto-16R,S-fluoro-PGE2 is (Z)-7-{(1R,2R,3R)-3-hydroxy-2[(4R,S)-4-fluoro-3-oxo-1-octyl]-5-oxocyclopentyl}-hept-5-enic acid. 13,14-dihydro-15-keto-20-ethyl-11-dehydroxy-11R-methyl-PGE2 methyl ester is methyl 7-{(1R,2S,3S)-3-methyl-2-[3-oxo-1-decyl]-5-oxo-cyclopentyl}-hept-5-enoate. 13,14-dihydro-6,15-diketo-19-methyl-PGE2 ethyl ester is ethyl 7-{(1R,2S,3S)-3-hydroxy-2-(7-methyl-3-oxo-1-octyl)-5-oxo-cyclopentyl}-6-oxo-heptanoate. 13,14-dihydro-15-keto-20-ethyl-PGF2α isopropyl ester is isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy- 2-{3-oxo-1-decyl)-cyclopentyl]hept-5-enoate. 13,14-dihydro-15-keto-20-methyl-PGF2α methyl ester is methyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{3-oxo-1-nonyl}-cyclopentyl]-hept-5-enonate.
Preferred prostanoic acid derivatives used in the present are those having an oxo group at position 15 of the prostanoic acid in place of the hydroxy group, or having at least one halogen atom on the prostanoic acid skeleton, or having both of these features. These derivatives may have a single bond (15-keto-PG1 compounds), a double bond (15-keto-PG2 compounds) between positions 5 and 6, or two double bonds (15-keto-PG3 compounds) between positions 5 and 6 as well as positions 17 and 18.
The term "halogen" refers to fluorine, chlorine, bromine and iodine with fluorine being preferred.
Examples of substitution products or derivatives include esters at the carboxy group at the alpha chain, pharmaceutically or physiologically acceptable salts, unsaturated derivatives having a double bond or a triple bond between positions 2 and 3 or positions 5 and 6, respectively, substituted derivatives having substituent(s) on carbon atom(s) at position 3, 6, 16, 17, 19 and/or 20 and compounds having lower alkyl or a hydroxy (lower) alkyl group at position 9 and/or 11 in place of the hydroxy group, of the above PGs.
Examples of substituents present in preferred compounds are as follows: Substituents on the carbon atom at position 3, 17 and/or 19 include lower alkyl, for example, C1-4 alkyl, especially methyl and ethyl. Substituents on the carbon atom at position 16 include lower alkyl e.g. methyl, ethyl etc., hydroxy and halogen atom e.g. chlorine, fluorine, phenyl and phenoxy, the last two being unsubstituted or substituted. Substituents on the carbon atom at position 20 include saturated and unsaturated lower alkyl e.g. C1-4 alkyl, lower alkoxy e.g. C1-4 alkoxy and lower alkoxy (lower)alkyl e.g C1-4 alkoxy-C1-4 alkyl Substituents on the carbon atom at position 6 include oxo group forming carboxyl. Stereochemistry of PGs having hydroxy, lower alkyl or lower (hydroxy)alkyl substituent on the carbon atom at position 9 and/or 11 may be alpha, beta or mixtures thereof.
Said derivatives may have an alkoxy, phenoxy or phenyl group at the end of the omega chain where the chain is shorter than the primary PGs.
In the present invention, preferred compounds are those having at least one halogen atom on the prostanoic acid derivative, and the position of halogen atom is not limited but preferredly on the omega chain and more preferredly one or two halogen atoms are present at position 16.
A group of preferred compounds used in the present invention has the formula (I) ##STR2## wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-members ring may have at least one double bond, Z is hydrogen or halogen, A is --CH2 OH, --COCH2 OH, --COOH or is functional derivative, R1 is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl, R2 is saturated or unsaturated, lower or mediumaliphatic hydrocarbon residue which is unsubstituted or substituted with oxo, hydroxy, halo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy, with the proviso the third carbon atom counted from 5-membered ring is substituted with an oxo group.
In the above formula, the term "unsaturated" in the definitions for R1 and R2 is intended to include at least one and optionally more then one double bond and/or triple bond isolatedly, separately or serially present between carbon atoms of the main and/or side chains. According to usual nomenclature, an unsaturation between two serial positions is represented by denoting the lower number of said two positions, and an unsaturation between two distal positions is represented by denoting both of the positions. Preferred unsaturation is a double bond at position 2 and a double or triple bond at position 5.
The term "lower or medium aliphatic hydrocarbon residue" refers to a straight or branched chain hydrocarbyl group having 1 to 14 carbon atoms (for a side chain, 1 to 3 carbon atoms being preferred) and preferably 2 to 8 carbon atoms for R1 and 6 to 12 carbon atoms for R2.
The term "halo" denotes fluoro, chloro, bromo and iodo.
The term "lower" is intended to include a group having 1 to 6 carbon atoms unless otherwise specified.
The term "lower alkyl" as a group or a moiety in hydroxy(lower)alkyl includes saturated and straight or branched chain hydrocarbon radicals containing 1 to 6, carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.
The term "lower alkoxy" refers to the group lower-alkyl-O- wherein lower alkyl is as defined above.
The term "hydroxy(lower)alkyl" refers to alkyl as defined above and substituted with at least one hydroxy group, e.g. hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 1-methyl-1-hydroxyethyl.
The term "lower alkanoyloxy" refers to a group of the formula: RCO--O-- wherein RCO-- is an acyl group formed by oxidation of a lower alkyl group as defined above, e.g. acetyl.
The term "cyclo(lower)alkyl" refers to a cyclic group formed by cyclization of a lower alkyl group as defined above.
The term "aryl" includes unsubstituted or substituted aromatic carbocyclic or heterocyclic (preferably monocyclic) groups, e.g. phenyl, tolyl, xylyl and thienyl. Examples of substituents are halo and halo(lower)alkyl wherein halo and lower alkyl being as defined above.
The term "aryloxy" refers to a group of the formula: ArO-- wherein Ar is aryl as defined above.
The term "functional derivative" of carboxy as A includes salts (preferably pharmaceutically acceptable salts), esters and amides.
Suitable "pharmaceutically acceptable salts" includes conventional non-toxic salt, and may be a salt with an inorganic base, for example a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), ammonium salt, a salt with an organic base, for example, an amine salt (e.g. methylamine salt, dimethylamine salt, cyclohexylamine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris(hydroxymethylamino)methane salt, monomethyl-monoethanolamine salt, procaine salt, caffeine salt, etc.), basic amino acid salt (e.g. arginine salt, lysine salt, etc.), tetraalkylammonium salt and the like. These salts can be prepared by the conventional process, for example from the corresponding acid and base or by salt interchange.
Examples of the esters are aliphatic esters, for example, lower alkyl ester e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, 1-cyclopropylethyl ester, etc., lower alkenyl ester e.g. vinyl ester, allyl ester, etc., lower alkynyl ester e.g. ethynyl ester, propynyl ester, etc., hydroxy(lower)alkyl ester e.g. hydroxyethyl ester, lower alkoxy(lower)-alkyl ester e.g. methoxymethyl ester, 1-methoxyetyl ester, etc., and aromatic esters, for example, optionally substituted aryl ester e.g. phenyl ester, tosyl ester, t-butylphenyl ester, salicyl ester, 3,4-di-methoxy-phenyl ester, benzamidophenyl ester etc., aryl(lower)alkyl ester e.g. benzyl ester, trityl ester, benzhydryl ester, etc. Examples of the amides are mono- or di- lower alkyl amides e.g. methylamide, ethylamide, dimethylamide, etc., arylamide e.g. anilide, toluidide, and lower alkyl- or aryl-sulfonylamide e.g. methylsulfonylamide, ethylsulfonylamide, tolylsulfonylamide etc.
Preferred examples of A include --COOH, --COOCH3, --COOCH2 CH3, --COOCH(CH3)2) and --CONHSO2 CH3.
The configuration of the ring and the α- and/or omega chain in the above formula (I) may be the same as or different from that in the primary PGs. However, the present invention also includes a mixture of a compound having a primary configuration and that of an unprimary configuration.
Examples of the typical compounds of the present invention are 15-keto-PGs, 13,14-dihydro-15-keto-PGs and their e.g. 6-keto-derivatives, Δ2 -derivatives, 3R,S-methyl-derivatives, 16R,S-methylderivatives, 16,16-dimethyl-derivatives, 16R,S-fluoroderivatives, 16,16-difluoro-derivatives, 17S-methylderivatives, 19-methylderivatives, 20-methyl-derivatives and 16-desbutyl-16-phenoxy derivatives.
When 15-keto-PG compounds of the present invention have a saturated bond between positions 13 and 14, these compounds may be in the keto-hermiacetal equilibrium by forming a hemiacetal between hydroxy group at position 11 and ketone at position 15.
The proportion of both tautomeric isomers, when presnt, varies depending on the structure of the rest of the molecule or kind of any substituent present and, sometimes, one isomer may predominantly be present in comparison with the other. However, in this invention, it is to be appreciated that the compounds used in the invention include both isomers. Further, while the compounds used in the invention may be represented by a structure or name based on keto-form regardless of the presence or absence of the isomers, it is to be noted that such structure or name does not intend elimination of the hemiacetal type of compounds.
In the present invention, any of the individual tautomeric isomers, a mixture thereof, or optical isomers, a mixture thereof, a racemic mixture, and other isomers such as steric isomers can be used in the same purpose.
Some of the compounds used in the present invention may be prepared by the method disclosed in Japanese Patent Publication (unexamined) No. A-52753/1989.
Alternatively, these compounds may be prepared by a process analogous to that described herein or to known processes.
A practical preparation of the prostanoic acid derivative, e.g. 13,14-dihydro-15-keto compounds, involves the following steps; referring to the synthetic charts(I) to (III), reaction of the aldehyde (2) prepared by the Collins oxidation of commercially available (-)-Corey lactone (1) with dimethyl (2-oxoheptyl)phosphate anion to give α,β-unsaturated ketone (3), reduction of the α,β-unsaturated ketone (3) to the corresponding saturated ketone (4), protection of the carbonyl group of the ketone (4) with a diol to the corresponding ketal (5), and deprotection of the p-phenylbenzoyl group to give the corresponding alcohol (6) followed by protection of the newly derived hydroxy group with dihydropyrane to give the corresponding tetrahydropyranyl ether (7). According to the above process, a precursor of PGEs wherein the ω-chain is a 13,14-dihydro-15-keto-alkyl group is prepared.
Using the above tetrahydropyranyl ether (7), 6-keto-PGE1 s (15) of which a group constituted with carbon atoms of position 5, 6 or 7 is --C5 H2 --C6 (O)--C7 H2 --, may be prepared in the following steps; reduction of the tetrahydropyranyl ether (7) with, for example, diisobutyl aluminum hydride to give the corresponding lactol (8), reaction of the lactol (8), with the ylide generated from (4-carboxybutyl)triphenyl phosphonium bromide followed by esterification (10), cyclization between the 5,6-double bond and the hydroxyl group at position 9 with NBS or iodine to give the halogenated compound (11), dehydrohalogenation of the compound (11) with, for example, DBU to give the 6-keto compound (13) followed by Jones oxidation and removal of the protecting groups.
Furthermore, PGE2 s (19) of which a group constituted with carbon atoms of position 5, 6 and 7 is --C7 H2 --C6 H═C5 H-- may be prepared in the following steps; as shown in the synthetic chart II, reduction of the above tetrahydropyranyl ether (7) to give the lactol (8), reaction of the resultant lactol (8) with the ylide derived from (4--carboxybutyl-)triphenyl phosphonium bromide to give the carboxylic acid (16) followed by esterification to give ester (17), Jones oxidation of the esters (17) to give the compound (18), and removal of the protecting groups.
Using the above tetrahydropyranyl ether (7) as the starting material, the compound having --C7 H2 --C6 H2 --C5 H2 -- may be prepared by using the same process as that for preparing PGE2 having --CH2 CH═CH-- and subjecting the resultant compound (18) to catalytic reduction to reduce the double bond between the position 5 and 6 followed by removal of the protective groups.
Synthesis of 5,6-dehydro-PGE2 s having --C7 H2 --C6 .tbd.C5 -- may be carried out by capturing a copper enolate formed by 1,4-addition of a monoalkylcopper complex or a dialkylcopper complex of the following formulae: ##STR3## to 4R-t-butyldimethylsilyloxy-2-cyclopenten-1-one with 6-alkoxycarbonyl-1-iodo-2-hexyne or the derivatives.
The 11-βtype PGEs can be prepared according to the synthetic chart III.
PGE derivatives having a methyl group at position 11 in place of hydroxy can be prepared by reacting a dimethyl copper complex with PGA-type compound obtained by subjecting 9-hydroxy-11-tosylate to the Jones oxidation. Alternatively, they can be prepared by protecting the carbonyl of saturated ketone (4) produced by reducing unsaturated ketone (3), eliminating p-phenylbenzoyl and tosylating the produced alcohol, treating with DBU to form a lactol, introducing the alpha-chain by Wittig reaction, oxidizing the alcohol at position 9 to give PGA-type compound, and reacting the product with dimethyl copper complex in order to introduce a methyl group into position 11 to give an 11-methyl-PGE-type compound, which on reduction with e.g. sodium borohydride gives an 11-methyl-PGF-type compound. An 11-hydroxymethyl-PGE-type compound, is obtained by a benzophenone-sensitized photoaddition of methanol of PGA-type compound, which is reduced with, e.g. sodium borohydride, to give an 11-hydroxymethyl-PGF-type compound. The synthetic route for the compounds used in the present invention is not limited to the that described above one and may vary using different protecting, reducing and/or oxidizating methods.
Corresponding other PG compounds can be produced analogously. ##STR4##
The compounds used in the present invention may be used as a medicine for animals and human beings and usually applied systemically or locally by such methods as oral administration, intravenous injection (including instillation), subcutaneous injection, suppository and the like. While the dosage will vary depending on the particular animal or human patient, age, body weight, symptom to be treated, desired therapeutic effect, administration route, term of treatment and the like, satisfactory effects will be obtained with the dosage of 0.001-500 mg/kg administered in 2 to 4 divided doses a day or as a sustained form.
As a solid composition of this invention for oral administration, tablets, troches, buccals, capsules, pills, powders, granules and the like are included. The solid composition containing one or more active substances is mixed with at least an inactive diluent, e.g. lactose, mannitol, glucose, hydrocypropyl cellulose, fine crystalline cellulose, starch, polyvinyl pyrolidone, magnesium aluminate metasilcate. The composition may contain additives other than the inactive diluent, for example, lubricants e.g., magnesium stearae, a disintegrator e.g. cellulose calcium gluconates, stabilizers e.g. α-, β- or γ-cyclodextrins, etherated cyclodextrins (e.g. dimethyl-α- , dimethyl-β-, trimethyl-β-, or hydroxypropyl-β-cyclodextrins), branched cyclodextins (e.g. glucosyl- or maltosyl-cyclodextrins), formyl cyclodextrins, sulfur-containing cyclodextrins, misoprotols or phospholipids. Such cyclodextrins may increase the stability of the compounds by forming an inclusion compounds. The stability may be often increased by forming lyposome with phospholipids. Tablets and pills may be coated with an enteric or gastroenteric film e.g. white sugar, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalates and the like, if necessary, and furthermore they may be covered with two or more layers. Additionally, the composition may be in the form of capsules made of substance easily absorbed e.g. gelatin. The composition may be in the form of buccals, when an immediated effect is desired. For this purpose, base e.g. glycerine, lactose may be used.
Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like and contain a generally used inactive diluent e.g. purified water or ethyl alcohol. The composition may contain additives e.g. wetting agents, suspending agents, sweeteners, flavors, perfumes and preservatives.
The composition of the present invention may be sprays which may contain one or more active ingredients and which can be prepared according to a well known methods.
An injection of this invention for non-oral administration includes serile aqueous or nonaqueous solutions, suspensions, and emulsions. Diluents for the aqueous solution or suspension include, for example, distilled water for injection, physiological saline and Ringer's solution. Diluents for the nonaqueous solution and suspension include, for example, propylene glycol, polyethylene glycol, vegetable oils e.g. olive oil, alcohols, e.g. ethanol and polysorbates. The composition may contain other additives, e.g. preservatives, wetting agents, emulsifying agents, dispersing agents and the like. These are sterilized by filtration through, e.g. a bacteria-retaining filter, compounding with a sterilizer, gas sterilization or radiation sterilization. These can be prepared by producing a sterilized water or a sterilized solvent for injection before use.
Another formulation according to the present invention is a rectal or vaginal suppository. This can be prepared by mixing at least one active compound according to the invention with a suppository base e.g. cacao butter and optionally containing nonionic surfactant for improving absorption.
The compounds used in the medicament according to the present invention have an effect of inducing decrease in potassium ion concentration or of improving excretion of potassium ion concentration in the blood into the intestines or as feces.
Accordingly, the compounds used in the present invention are useful for treatment (e.g. prevention, cure, relief and arrest or relief of development) of conditions wherein potassium ion level in the blood is elevated and of disorder in the balance of electrolytes such as uremia irrespective of cause, e.g. disease, drug or food.
A more complete understanding of the present invention can be obtained by reference to the following Formulation Examples and Test Examples which are provided herein for purpose of illustration only and are not intended to limit the scope of the invention.
13,14-dihydro-15-keto-16R,S-fluoro-PGE2 : 50 mg lactose: 200 mg
The above ingredients were mixed and filled in hard gelatin capsules.
______________________________________ (Powder, for injection) (Parts by weight) ______________________________________ 13,14-dihydro-15-keto-16,16-difluoro-PGE.sub.2 1 mannitol 5 distilled water 0.4 ______________________________________
The above ingredients were mixed, stirred, sterilized, filtered and lyophilized to give powders for injection.
______________________________________ (Injectable solution) (Parts by weight) ______________________________________ 13,14-dihydro-15-keto-16,16-dimethyl-PGE.sub.2 0.2 aomion surfactant 2 distilled water 98 ______________________________________
The above ingredients were mixed and sterilized to give and injectable solution.
13,14-dihydro-15-keto-16,16-difluoro-20-ethyl-PGE2 (50 mg) dissolved in methanol (10 ml) was mixed with mannitol (18.5 g). The mixture was screened (with a sieve, the pore size of which being 30 mm in diameter), dried and screened again. The powders thus obtained were mixed with fine-grain silica gel (Aerosil*, 200 g) and filled in No.3 hard gelatin capsules (100) to give enteric capsules which contain 0.5 mg of 13,14-dihydro-15-keto-16,16-difluoro-20-ethyl-PGE2 per capsule.
______________________________________ (Powders for oral administration) (Parts by weight) ______________________________________ 13,14-dihydro-15-keto-16,16-difluoro-PGF.sub.2α 5 methyl ester light anhydrous silicic acid 5 Abicel ® 20 lactose 70 ______________________________________ ® Trade Mark
The above ingredients were mixed to give powders for oral administration.
______________________________________ (Soft gelatine capsules) (Parts by weight) ______________________________________ 13,14-dihydro-15-keto-20-methyl-PGE.sub.2 1 methyl ester light anhydrous silicic acid 899 Panaste ® 20 ______________________________________ ® Trade Mark
The above ingredients were mixed and filled in soft gelatine capsules.
16-desbutyl-13,14-dihydro-15-keto-16-(m-trifluormethyl)phenoxy-PGF2.alpha. methyl ester (50 mg) dissolved in methanol (10 ml) was mixed with mannitol (18.5 g). The mixture was screened (with a sieve, the pore size of which being 30 mm in diameter), dried for 90 minutes at 30° C. and screened again. The powders thus obtained were mixed with fine-grain silica gel (Aerosil*, 200 g) and filled in No.3 hard gelatin capsules (100) to give enteric capsules which contain 0.5 mg of 13,14-dihydro-15-keto-16-desbutyl-16-m-trifluoromethylphenoxy-PGF2.alpha. methyl ester per capsule.
In the above formulation examples, the active ingredient can be replaced by any other compound within the compounds used in the invention.
Thirty male Crj: Wistar rats (5 weeks old, obtained from Charles River) were quarantined and acclimatized for about 1 weeks. Then the animals were divided into groups with even mean weight and standard deviation.
All the animals were bred in individual stainless steel cages (190×380×180 mm) at a temperature of 24°±1° C. and with a humidity of 55±5% with 12 hour light and dark cycle (illumination 8:00-20:00) supplying with fresh aseptic air. They were bred (with NMF, Oriental Yeast Industries, Ltd) and waterad ad libitum exept the last day of medication, on which day they were fasted.
Test compound 13,14-dihydro-15-keto-16-R,S-fluoroprostaglandin E2 was dissolved in an aliquot of ethanol and the solution was evaporated in a test tube under nitrogen. The residue was combined with a predetermined amount of distilled water and sonicated to form a homogeneous test suspension.
Starting from day 1 to day 14, rats received (between 9:00 and 12:00) a daily dosage of 1 ml/1 kg of the test suspension through a disposable plastic sylinge (1 ml) equipped with an P.O. administration needle for rat based on the body weight measured just before the administration.
Design of the experiment was as follows:
______________________________________ Group Dose (mg/kg) Number of rats ______________________________________ 1 0 5 2 0.1 5 3 2.0 5 ______________________________________
All the animals were observed twice a day for any mortality and general conditions such as diarrhea except the last day, on which observation was made only once directly before the post mortem. The body weight and intake were measured every day at the predetermined time (between 9:00-10:00) before the medication Urine collection (24 hr) was made 3 hours after the medication under fasting on day 13.
Directly after the last medication, rats were sacrificed by cervical dislocation and subjected to celiotomy. Intestine was ligated at pyloric part of stomach and upper cecal part. The whole small intestine was removed and intraintestinal content was collected, measured a volume and centrifuged for 5 minutes at 1000 rpm and suppernatant was separated.
The urine, serum and supernatant were assayed for electoylte concentrations.
The results are summarized in the following Tables.
TABLE 1 __________________________________________________________________________ Body weight Weight (g) Dosage Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 __________________________________________________________________________ 0 n 5 5 5 5 5 5 5 5 5 5 5 5 5 5 (Con- mean 277.7 282.0 291.9 296.2 307.3 312.3 320.4 329.7 334.9 340.8 346.4 350.1 356.0 318.0 trol) S.D. 4.1 7.9 6.7 7.6 10.8 10.9 12.5 10.8 11.7 14.1 15.6 15.2 16.5 13.5 0.1 n 5 5 5 5 5 5 5 5 5 5 5 5 5 5 mg/kg mean 277.6 281.8 293.4 297.1 300.3 310.8 320.8 330.4 335.8 339.4 344.5 351.3 355.9 317.0 S.D. 4.1 4.9 7.4 6.0 13.0 7.1 6.7 8.4 8.3 6.6 12.4 8.8 11.1 10.9 2.0 n 5 5 5 5 5 5 5 5 5 5 5 5 5 5 mg/kg mean 277.6 274.7 283.0 286.7 296.9 300.7 309.6 319.9 322.7 327.8 330.8 334.1 345.9 304.9 S.D. 3.0 5.0 3.7 4.5 4.8 4.8 4.6 8.2 6.5 8.7 6.8 7.7 7.9 6.6 __________________________________________________________________________
TABLE 2 __________________________________________________________________________ Intake Intake (g) Dosage Day 1 2 3 4 5 6 7 8 9 10 11 12 __________________________________________________________________________ 0 n 5 5 5 5 5 5 5 5 5 5 5 5 (Control) mean 27.8 28.5 29.8 28.2 28.2 30.0 29.1 29.1 30.1 29.3 29.9 29.7 S.D. 3.1 2.6 2.6 1.9 3.0 2.1 2.4 2.4 2.7 3.1 2.1 2.9 0.1 mg/kg n 5 5 5 5 5 5 5 5 5 5 5 5 mean 25.9 28.6 29.1 24.4 29.3 30.7 29.5 29.3 28.8 29.4 29.1 28.6 S.D. 2.9 1.3 1.4 6.6 2.5 1.5 2.5 0.1 0.9 3.4 1.0 1.7 2.0 mg/kg n 5 5 5 5 5 5 5 5 5 5 5 5 mean *19.3 24.8 26.1 25.2 26.3 28.1 29.0 27.8 28.7 29.1 28.0 30.9 S.D. 1.4 1.6 2.6 2.3 2.3 2.3 2.7 1.0 1.0 2.7 2.7 2.5 __________________________________________________________________________ *0.05 > P > 0.01 (DUNNET ANALYSIS)
TABLE 3 __________________________________________________________________________ Electrolyte (I.C.: Intraintestinal content) Urine Na.sup.+ K.sup.+ Cl.sup.- I.C. (3 hr) I.C. Urine I.C. Urine I.C. Urine Dosage ml ml mEq mEq mEq mEq mEq mEq __________________________________________________________________________ 0 mean 2.2 3.9 0.38 0.17 0.022 0.30 0.148 0.175 (Control) S.D. 1.2 2.1 0.17 0.09 0.010 0.16 0.082 0.121 0.1 mg/kg mean 2.0 1.6 0.27 0.07 *0.045 0.20 0.172 0.125 S.D. 0.4 0.8 0.06 0.06 0.017 0.12 0.045 0.126 2.0 mg/kg mean *4.8 1.8 0.64 0.09 **0.096 0.12 **0.527 0.059 S.D. 1.8 1.0 0.25 0.06 0.027 0.05 0.217 0.033 __________________________________________________________________________ **0.1 > P *0.05 > P > 0.01 (DUNNET analysis)
From the above results, it can be easily understood that excretion of potassium ion into the intestine was dose-dependently increased in the medicated group. Almost no influence was observed in the medicated group in respect to body weight and water intake.
Male Wistar rats (8 weeks old) were anesthetized with pentobarbital (40 mg/kg) and cortices of their left kidneys were partly removed. After 3 to 7 days, their whole right kidneys were removed. The overall excision of kidneys were 1 plus three fourth to 1 plus for fifth. As the test compound, 13,14-dihydro-15-keto-16-R,S-fluoroprostaglandin E2 methyl ester was suspended in distilled water and administered orally to the surgically injured animals (3 per group) at a dose of 2 mg/kg/ml on continuous 14 days starting from the day after 14 days the operation. The dose was increased to 3 mg/kg on and after day 10 of administration because animals can not to have diarrhea about that day. The control group received the same volume of distilled water. One week after the start of medication, blood samples were taken from tail vein of each animal and serum was assayed for Na, K and Cl concentrations.
In addition two weeks after the start of medication, the total blood was taken from ventral aorta of each animal and serum was assayed for Na, K and Cl concentrations. After 2 hours of the last medication, feces were collected and extracted with a predetermined amount of distilled water. The extract was centrifuged and the supernatant was assayed for electrolytes. Weight and water intake of the rats were measured at almost daily.
The results are summarized in the following Table.
TABLE 4 ______________________________________ Weight (g) Control group Test group Days of medication mean SD mean SD ______________________________________ 0 332.2 33.3 341.7 23.9 1 345.9 35.3 321.8 24.3 2 324.0 23.0 311.8 15.7 3 345.4 25.7 313.8 10.8 4 339.4 22.5 319.3 10.3 5 344.9 25.1 336.7 12.8 7 352.7 31.0 351.6 15.5 8 348.9 25.7 341.9 17.4 9 335.6 26.0 341.0 15.6 10 360.6 32.8 348.6 23.5 11 360.6 21.1 359.6 20.3 12 355.2 28.2 356.7 17.1 13 357.9 27.2 359.5 20.2 14 337.7 8.6 364.8 15.0 ______________________________________
TABLE 5 ______________________________________ Water intake (ml/day) Control group Test group Days of medication mean SD mean SD ______________________________________ 1 77.6 12.4 44.2 7.1 2 72.1 10.2 51.4 4.5 3 48.3 13.7 4 69.0 10.2 66.3 16.3 5 74.6 9.5 99.8 18.3 8 70.6 5.1 99.8 18.3 9 73.4 7.0 95.9 16.1 10 75.4 5.0 11 71.3 7.1 88.8 5.2 12 73.8 3.2 81.5 9.8 13 72.1 4.3 89.5 5.9 ______________________________________
TABLE 6 ______________________________________ Serum Group Na K Cl ______________________________________ untreated mean 140.3 4.03 108.6 ±SD ±5.4 ±0.21 ±2.9 2 weeks after mean 142.6 4.42 104.0 operation ±SD ±1.7 ±0.30 ±1.0 medicated mean 141.7 3.79 104.4 control ±SD ±5.6 ±0.69 ±3.8 1 week mean 144.3 3.57** 107.1 medicated ±SD ±1.8 ±0.66 ±2.4 medicated mean 142.9 4.04 104.2 control ±SD ±4.3 ±0.39 ±2.9 weeks mean 147.5 3.32** 108.7 medicated ±SD ±1.7 ±0.12 ±1.0 ______________________________________ *P < 0.05 **P < 0.1
TABLE 7 ______________________________________ Serum control 2 mg/kg mean ± S.D. mean ± S.D. ______________________________________ Na (mmol/l) 142.9 ± 4.3 147.5 ± 1.7 K (mmol/l) 4.64 ± 0.39 3.32 ± 0.12 Cl (mmol/l) 104.2 ± 2.9 108.7 ± 1.0 ______________________________________
TABLE 8 ______________________________________ Feces (2 weeks medication) Na K Cl group mg mg mg ______________________________________ control mean 0.28 1.74 4.51 test mean 14.01 21.46 40.35 ±SD ±10.35 ±6.35 ±11.03 ______________________________________
For the above result, it can be clearly seen that, after two weeks of renal injury, potassium ion concentration in the blood was increased in the injured group by about 10% as compared with the intact group and that, after two weeks of the onset of medication, potassium ion concentration was significantly decreased in the medicated group as compared with the control group and further, 2 hours after the medication, electrolyte in feces of the medicated group were twelve times larger than in feces of the control group.
The procedure of Test Example 2 was repeated except that 13,14-dihydro-15-keto-16,16-difluoro-PGE2 (1.0 mg/kg) was used as the test compound. Contents of electorlyte in feces (after 5 days of medication) and in the serum (after 7 days of medication) are shown in the following Tables.
TABLE 9 ______________________________________ Feces day Na mg K mg Cl mg ______________________________________ 5 Control Mean 0.60 1.28 3.85 S.D. ±0.42 ±0.52 ±1.42 Medicated Mean 4.47* 7.24** 13.57*** S.D. ±2.15 ±1.55 ±2.55 ______________________________________
TABLE 10 ______________________________________ Serum day Na mmol/l K mmol/l Cl mmol/l ______________________________________ 5 Control Mean 139.4 10.09 105.2 S.D. ±2.1 ±1.60 ±1.5 Medicated Mean 141.1 9.22 105.4 S.D. ±3.4 ±0.60 ±3.8 ______________________________________
Claims (16)
1. A method for inducing decrease in potassium ion concentration in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, .[.a derivative of a prostanoic acid having the skeleton.]. ##STR5## .Iadd.a 15-keto-16-mono- or di-haloprostaglandin represented by formula (I) .Iaddend.in an amount effective in inducing decrease in potassium ion concentration in the blood .[.wherein said concentration is increased.]..Iadd.: ##STR6##.Iaddend. wherein X and Y are independently selected from the group consisting of hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl and oxo, with the proviso that at least one of X and Y is not hydrogen; the five-membered ring shown in structural formula (I) may contain at least one double bond; Z is hydrogen or halogen; A is --CH2 OH, --COCH2 OH, --COOH or a functional derivative thereof; R1 is a bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl; R2 is a saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with oxo, hydroxy, halo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy; R2 contains at least four carbon atoms, with the proviso that the third carbon atom of R2 removed from the five-membered ring being substituted with an oxo group and the fourth carbon atom of R2 removed from the five-membered ring being substituted with one or two halogen atoms.
2. The method according to claim 1, for compensating reduced renal function.
3. The method according to claim 1, for treating renal insufficiency. .[.4. The method according to claim 1, wherein the prostanoic acid derivative has one or two halogen atoms at position 16..]. .[.5. The method according to claim 1, wherein the prostanoic acid derivative has an oxo group at
position 15..]. 6. The method according to claim 1, wherein the prostanoic
acid derivative has a saturated bond between positions 13 and 14. 7. The method according to claim 1, wherein the prostanoic acid is a
prostaglandin derivative. 8. The method according to claim 1, wherein the prostanoic acid derivative is a 15-keto-16-mono- or di-fluoroprostaglandin
compound. 9. A method for improving extracorporeal excretion of potassium ion in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, .[.a derivative of a prostanoic acid having the skeleton.]. ##STR7## .Iadd.a 15-keto-16-mono- or di-haloprostaglandin represented by formula (I) .Iaddend.in an amount effective in improving extracorporeal excretion of potassium ion .[.concentration is increased.]..Iadd.: ##STR8##.Iaddend. wherein X and Y are independently selected from group consisting of hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl and oxo, with the proviso that at least one of X and Y is not hydrogen; the five-membered ring shown in structural formula (I) may contain at least one double bond; Z is hydrogen or halogen; A is --CH2 OH, --COCH2 OH, --COOH or a functional derivative thereof; R1 is a bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl; R2 is a saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with oxo, hydroxy, halo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy; R2 contains at least four carbon atoms, with the proviso that the third carbon atom of R2 removed from the five-membered ring being substituted with an oxo group and the fourth carbon atom of R2 removed from the five-membered ring being substituted with one or two
halogen atoms. 10. The method according to claim 9, wherein the excretion
occurs through the intestine. 11. The method according to claim 9, for
treating hyperkalemia. 12. The method according to claim 9, for
compensating reduced renal function. 13. The method according to claim 9, for treating renal insufficiency. .[.14. The method according to claim 9, wherein the prostanoic acid derivative has one or two halogen atoms at position 16..]. .[.15. The method according to claim 9, wherein the
prostanoic acid derivative has an oxo group at position 15..]. 16. The method according to claim 9, wherein the prostanoic acid derivative has a
saturated bond between positions 13 and 14. 17. The method according to
claim 9, wherein the prostanoic acid is a prostaglandin derivative. 18. The method according to claim 9, wherein the prostanoic acid
derivative is a 15-keto-16-mono- or di-fluoroprostaglandin compound. 19. The method according to claim 7 wherein the derivative of a prostanoic
acid is a PGA, PGB, PGC, PGD, PGE, PGF, PGG, PGH, PGI, or PGJ. 20. The method of claim 17 wherein the derivative of a prostanoic acid is a PGA, PGB, PGC, PGD, PGE, PGF, PGG, PGH, PGI or PGJ.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/953,786 USRE34756E (en) | 1989-07-27 | 1992-09-30 | Excretion of potassium ion by prostanoic acid derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1-197090 | 1989-07-27 | ||
JP19709089 | 1989-07-27 | ||
US07/557,834 US5075334A (en) | 1989-07-27 | 1990-07-26 | Excretion of potassium ion by prostanoic acid derivatives |
US07/953,786 USRE34756E (en) | 1989-07-27 | 1992-09-30 | Excretion of potassium ion by prostanoic acid derivatives |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/557,834 Reissue US5075334A (en) | 1989-07-27 | 1990-07-26 | Excretion of potassium ion by prostanoic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE34756E true USRE34756E (en) | 1994-10-11 |
Family
ID=16368563
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/557,834 Ceased US5075334A (en) | 1989-07-27 | 1990-07-26 | Excretion of potassium ion by prostanoic acid derivatives |
US07/953,786 Expired - Lifetime USRE34756E (en) | 1989-07-27 | 1992-09-30 | Excretion of potassium ion by prostanoic acid derivatives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/557,834 Ceased US5075334A (en) | 1989-07-27 | 1990-07-26 | Excretion of potassium ion by prostanoic acid derivatives |
Country Status (6)
Country | Link |
---|---|
US (2) | US5075334A (en) |
EP (1) | EP0410652B1 (en) |
JP (1) | JP2609479B2 (en) |
AT (1) | ATE122563T1 (en) |
CA (1) | CA2022323C (en) |
DE (1) | DE69019431T2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040105895A1 (en) * | 2001-02-06 | 2004-06-03 | Ash Stephen R | Monovalent-selective cation exchangers as oral sorbent therapy |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020133009A1 (en) * | 2001-03-13 | 2002-09-19 | Lambrou George N. | Method for opening potassium channels |
WO2006016695A1 (en) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Preventive and/or remedy for hyperkalemia containing ep4 agonist |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0281239A2 (en) * | 1987-01-28 | 1988-09-07 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandins of the D series, and tranquilizers and soporifics containing the same |
EP0284180A1 (en) * | 1987-01-28 | 1988-09-28 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
EP0292177A1 (en) * | 1987-05-15 | 1988-11-23 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Fervescence composition |
EP0308135A2 (en) * | 1987-09-18 | 1989-03-22 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
EP0310305A2 (en) * | 1987-10-02 | 1989-04-05 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Cathartics |
EP0330511A2 (en) * | 1988-02-26 | 1989-08-30 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Stabilization of 13,14-dihydro-15-ketoprostaglandins |
EP0342003A1 (en) * | 1988-05-11 | 1989-11-15 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Use of 15-ketoprostaglandin E or F compounds for uterine contraction |
EP0343904A1 (en) * | 1988-05-23 | 1989-11-29 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Hypersphyxia causing composition |
EP0345951A1 (en) * | 1988-05-11 | 1989-12-13 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Tracheobronchodilator |
EP0289349B1 (en) * | 1987-04-30 | 1992-01-29 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandins of the f series |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6027669B2 (en) * | 1976-12-30 | 1985-06-29 | ジ・アツプジヨン・カンパニ− | Prostaglandin analogs |
DE3115997A1 (en) * | 1981-04-13 | 1982-11-04 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Novel prostaglandins and prostacyclins, process for their preparation and their use as medicaments |
DE3121155A1 (en) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | NEW CARBACYCLINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
DE3221193A1 (en) * | 1982-05-28 | 1983-12-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | NEW CARBACYCLINESTERS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
DE3322893A1 (en) * | 1983-06-23 | 1985-01-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | NEW PROSTACYCLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
DE3608088C2 (en) * | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmaceutical preparations containing cyclodextrin clathrates of carbacyclin derivatives |
DE3725031A1 (en) * | 1987-07-24 | 1989-02-02 | Schering Ag | NEW 9-SUBSTITUTED CARBACYCLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
-
1990
- 1990-07-20 AT AT90307944T patent/ATE122563T1/en not_active IP Right Cessation
- 1990-07-20 DE DE69019431T patent/DE69019431T2/en not_active Expired - Lifetime
- 1990-07-20 EP EP90307944A patent/EP0410652B1/en not_active Expired - Lifetime
- 1990-07-24 JP JP2196743A patent/JP2609479B2/en not_active Expired - Fee Related
- 1990-07-25 CA CA002022323A patent/CA2022323C/en not_active Expired - Lifetime
- 1990-07-26 US US07/557,834 patent/US5075334A/en not_active Ceased
-
1992
- 1992-09-30 US US07/953,786 patent/USRE34756E/en not_active Expired - Lifetime
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0281239A2 (en) * | 1987-01-28 | 1988-09-07 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandins of the D series, and tranquilizers and soporifics containing the same |
EP0284180A1 (en) * | 1987-01-28 | 1988-09-28 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
EP0289349B1 (en) * | 1987-04-30 | 1992-01-29 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandins of the f series |
EP0292177A1 (en) * | 1987-05-15 | 1988-11-23 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Fervescence composition |
EP0308135A2 (en) * | 1987-09-18 | 1989-03-22 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
EP0310305A2 (en) * | 1987-10-02 | 1989-04-05 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Cathartics |
EP0330511A2 (en) * | 1988-02-26 | 1989-08-30 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Stabilization of 13,14-dihydro-15-ketoprostaglandins |
EP0342003A1 (en) * | 1988-05-11 | 1989-11-15 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Use of 15-ketoprostaglandin E or F compounds for uterine contraction |
EP0345951A1 (en) * | 1988-05-11 | 1989-12-13 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Tracheobronchodilator |
EP0343904A1 (en) * | 1988-05-23 | 1989-11-29 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Hypersphyxia causing composition |
Non-Patent Citations (17)
Title |
---|
Acta Physiol. Scand. (1966), 66, 509 510. * |
Acta Physiol. Scand. (1966), 66, 509-510. |
Biological Abstracts, Biosis No. 67059604; L. H. Norby et al.: "Possible role for impaired renal prostaglandin production in pathogenesis of hyporeninemic hpoaldosteronism" & Lancet 2 (*100). 1978 1118-1121. |
Biological Abstracts, Biosis No. 67059604; L. H. Norby et al.: Possible role for impaired renal prostaglandin production in pathogenesis of hyporeninemic hpoaldosteronism & Lancet 2 (*100). 1978 1118 1121. * |
Chem. Abst. 90: 118674 (1979). * |
E. Anggard, "The Biological Activites of Three Metabolites of Prostaglandin E1 ", Acta physiol. scand., (1966), 66, 509-510. |
E. ngg rd, The Biological Activites of Three Metabolites of Prostaglandin E 1 , Acta physiol. scand. , (1966), 66, 509 510. * |
Inazu et al, "Effect of 13, 14-Dihydroprostaglandin F2α on Steroid Biosynthesis in Rat Ovary", Japan. J. Pharmacol., (1981), 31, 301-303. |
Inazu et al, Effect of 13, 14 Dihydroprostaglandin F 2 on Steroid Biosynthesis in Rat Ovary , Japan. J. Pharmacol. , (1981), 31, 301 303. * |
Index Medicus, (item 1 from file: 155), Sy. Tan et al.: "Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism:" & Ann Intern Med May 1979, 90 (5) pp. 783-785. |
Index Medicus, (item 1 from file: 155), Sy. Tan et al.: Indomethacin induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism: & Ann Intern Med May 1979, 90 (5) pp. 783 785. * |
Kirk Othmer Encyclopedia of Chemical Technology , 3rd Ed., Supplement Volume, p. 719 (1978). * |
Kirk-Othmer Encyclopedia of Chemical Technology, 3rd Ed., Supplement Volume, p. 719 (1978). |
Prostaglandins, 11, 809 827 (1976). * |
Prostaglandins, 11, 809-827 (1976). |
Prostaglandins, vol. 20, No. 1, Jul. 1980, pp. 15 23; J. Hahn et al.: Induction of renin release by exogenous prostaglandins in hporeninemic hypoaldosteronism . * |
Prostaglandins, vol. 20, No. 1, Jul. 1980, pp. 15-23; J. Hahn et al.: "Induction of renin release by exogenous prostaglandins in hporeninemic hypoaldosteronism". |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040105895A1 (en) * | 2001-02-06 | 2004-06-03 | Ash Stephen R | Monovalent-selective cation exchangers as oral sorbent therapy |
Also Published As
Publication number | Publication date |
---|---|
JPH03130227A (en) | 1991-06-04 |
US5075334A (en) | 1991-12-24 |
DE69019431T2 (en) | 1995-09-14 |
EP0410652A2 (en) | 1991-01-30 |
DE69019431D1 (en) | 1995-06-22 |
JP2609479B2 (en) | 1997-05-14 |
CA2022323C (en) | 1995-07-25 |
CA2022323A1 (en) | 1991-01-28 |
ATE122563T1 (en) | 1995-06-15 |
EP0410652A3 (en) | 1992-03-11 |
EP0410652B1 (en) | 1995-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5686487A (en) | Treatment of cataract with 15-keto-prostaglandin compounds | |
EP1392318B1 (en) | 15-keto-prostaglandins for treating drug-induced constipation | |
US5773471A (en) | Treatment of optic nerve disorder with prostanoic acid compounds | |
EP0345951B1 (en) | Tracheobronchodilator | |
US5164415A (en) | Treatment of pancreatic disease with 15-keto-prostaglandin compounds | |
US5346921A (en) | Treatment of inflammation with 15-keto-prostaglandin compounds | |
KR20120045051A (en) | Derivatives of prostaglandins for treating abdominal discomfort | |
EP0424156B1 (en) | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds | |
US5397797A (en) | Treatment of ocular hypertension with an ocular synergistic combination | |
EP0430551B1 (en) | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds | |
US5254588A (en) | Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds | |
USRE34756E (en) | Excretion of potassium ion by prostanoic acid derivatives | |
CA2030344C (en) | Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds | |
US5126372A (en) | Excretion of nonprotein nitrogen into the intestine by prostanoic acid derivatives | |
US5256696A (en) | Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds | |
EP0501678B1 (en) | Treatment of ocular hypertension with a synergistic combination | |
US5234954A (en) | Treatment of hyperlipidemia with 15-keto-prostaglandin compounds | |
EP0469782B1 (en) | Treatment of cataract with prostacyclin compounds | |
EP0410646B1 (en) | Treatment of hyperlipidemia with 15-keto-prostaglandin compounds | |
US5175189A (en) | Treatment of ocular hypertension with a synergistic combination for ophthalmic use | |
JPH089544B2 (en) | Intestinal excretion agent | |
JPH03163024A (en) | Treating agent for hyperlipemia and reducing agent for lipid ingredient in blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: SUCAMPO AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO;REEL/FRAME:017411/0585 Effective date: 20051214 |